Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133high cancer stem cells in vitro and in vivo

Clinical Immunology

Volumn 149, Issue 1, 2013, Pages 156-168

  Huang, Jianhua ^a   Li, Chonghui ^a   Wang, Yao ^a   Lv, Haiyan ^a   Guo, Yelei ^a   Dai, Hanren ^a   Wicha, Max S ^b   Chang, Alfred E ^b   Li, Qiao ^b,c  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Bispecific antibody (BsAb); ; Cancer stem cell (CSC); ; CD133; CD3; ; Cytokine induced killer (CIK) cells;

Indexed keywords

BISPECIFIC ANTIBODY; CD133 BISPECIFIC ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CANCER STEM CELL; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

BISPECIFIC ANTIBODY (BSAB);; CANCER STEM CELL (CSC);; CD133; CD3;; CYTOKINE INDUCED KILLER (CIK) CELLS;;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, CD3; CELL LINE, TUMOR; CYTOKINE-INDUCED KILLER CELLS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; MICE; MICE, NUDE; NEOPLASMS; NEOPLASTIC STEM CELLS; PEPTIDES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883244302     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.07.006     Document Type: Article

References (48)

1. Ma S., Lee T.K., Zheng B.J., Chan K.W., Guan X.Y. CD133+HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27:1749-1758.
2. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
3. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
4. Koch U., Krause M., Baumann M. Cancer stem cells at the crossroads of current cancer therapy failures-radiation oncology perspective. Semin. Cancer Biol. 2010, 20:116-124.
5. Mimeault M., Batra S.K. New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histol. Histopathol. 2010, 25:1057-1073.
6. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 13:313-323.
7. Klonisch T., Wiechec E., Hombach-Klonisch S., Ande S.R., Wesselborg S., Schulze-Osthoff K., Los M. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Med. 2008, 14:450-460.
8. Mimeault M., Hauke R., Mehta P.P., Batra S.K. Recent advances on cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J. Mol. Cell Med. 2007, 11:981-1011.
9. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 2006, 12:1167-1174.
10. Ning N., Pan Q., Zheng F., Teitz-Tennenbaum S., Egenti M., Yet J., Li M., Ginestier C., Wicha M.S., Moyer J.S., Prince M.E.P., Xu Y., Zhang X., Huang S., Chang A.E., Li Q. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012, 72:1853-1864.
11. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
12. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
13. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., Conticello C., Ruco L., Peschle C., De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008, 15:504-514.
14. Suetsugu A., Nagaki M., Aoki H., Motohashi T., Kunisada T., Moriwaki H. Characterization of CD133+hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem. Biophys. Res. Commun. 2006, 351:820-824.
15. Monzani E., Facchetti F., Galmozzi E., Corsini E., Benetti A., Cavazzin C., Gritti A., Piccinini A., Porro D., Santinami M., Invernici G., Parati E., Alessandri G., La Porta C.A. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer 2007, 43:935-946.
16. Curley M.D., Therrien V.A., Cummings C.L., Sergent P.A., Koulouris C.R., Friel A.M., Roberts D.J., Seiden M.V., Scadden D.T., Rueda B.R., Foster R. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009, 27:2875-2883.
17. Florek M., Haase M., Marzesco A.M., Freund D., Ehninger G., Huttner W.B., Corbeil D. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 2005, 319:15-26.
18. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
19. Ong C.W., Kim L.G., Kong H.H., Low L.Y., Iacopetta B., Soong R., Salto-Tellez M. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod. Pathol. 2010, 23:450-457.
20. Sartelet H., Imbriglio T., Nyalendo C., Haddad E., Annabi B., Duval M., Fetni R., Victor K., Alexendrov L., Sinnett D., Fabre M., Vassal G. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway. Histopathology 2012, 6:1365-2559.
21. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. Cancer 2011, 2:363-368.
22. Olioso P., Giancola R., Di Riti M., Contento A., Accorsi P., Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol. Oncol. 2009, 27:130-139.
23. Tita-Nwa F., Moldenhauer G., Herbst M., Kleist C., Ho A.D., Kornacker M. Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells. Cancer Immunol. Immunother. 2007, 56:1911-1920.
24. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
25. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., Blume K.G., Weissman I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med. 1991, 174:139-149.
26. Emberley E.D., Murphy L.C., Watson P.H. S100 proteins and their influence on pro-survival pathways in cancer. Biochem. Cell Biol. 2004, 82:508-515.
27. Ferrandina G., Petrillo M., Bonanno G., Scambia G. Targeting CD133 antigen in cancer. Expert Opin. Ther. Targets 2009, 13:823-837.
28. Wu Y., Wu P.Y. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009, 18:1127-1134.
29. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T., Yamamoto J., Shimada K., Sakamoto M., Hirohashi S., Ohashi Y., Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 2000, 356:802-807.
30. Hontscha C., Borck Y., Zhou H., Messmer D., Schmidt-Wolf I.G. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J. Cancer Res. Clin. Oncol. 2011, 137:305-310.
31. Smith L.M., Nesterova A., Ryan M.C., Duniho S., Jonas M., Anderson M., Zabinski R.F., Sutherland M.K., Gerber H.P., Van Orden K.L., Moore P.A., Ruben S.M., Carter P.J. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br. J. Cancer 2008, 99:100-109.
32. Arumugam T., Logsdon C.D. S100P: a novel therapeutic target for cancer. Amino Acids 2011, 41:893-899.
33. Ohuchida K., Mizumoto K., Egami T., Yamaguchi H., Fujii K., Konomi H., Nagai E., Yamaguchi K., Tsuneyoshi M., Tanaka M. S100P is an early developmental marker of pancreatic carcinogenesis. Clin. Cancer Res. 2006, 12:5411-5416.
34. Rehbein G., Simm A., Hofmann H.S., Silber R.E., Bartling B. Molecular regulation of S100P in human lung adenocarcinomas. Int. J. Mol. Med. 2008, 22:69-77.
35. Guerreiro Da Silva I.D., Hu Y.F., Russo I.H., Ao X., Salicioni A.M., Yang X., Russo J. S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. Int. J. Oncol. 2000, 16:231-240.
36. Fuentes M.K., Nigavekar S.S., Arumugam T., Logsdon C.D., Schmidt A.M., Park J.C., Huang E.H. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis. Colon Rectum 2007, 50:1230-1240.
37. Wang Q., Zhang Y.N., Lin G.L., Qiu H.Z., Wu B., Wu H.Y., Zhao Y., Chen Y.J., Lu C.M. S100P, a potential novel prognostic marker in colorectal cancer. Oncol. Rep. 2012, 28:303-310.
38. Wang G., Platt-Higgins A., Carroll J., de Silva Rudland S., Winstanley J., Barraclough R., Rudland P.S. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res. 2006, 66:1199-1207.
39. Arumugam T., Simeone D.M., Van Golen K., Logsdon C.D. S100P promotes pancreatic cancer growth, survival, and invasion. Clin. Cancer Res. 2005, 11:5356-5364.
40. Jiang H., Hu H., Tong X., Jiang Q., Zhu H., Zhang S. Calcium-binding protein S100P and cancer: mechanisms and clinical relevance. J. Cancer Res. Clin. Oncol. 2012, 138:1-9.
41. Schneckenleithner Christine, Bago-Horvath Zsuzsanna, Dolznig Helmut, Neugebauer Nina, Kollmann Karoline, Kolbe Thomas, Decker Thomas, Kerjaschki Dontscho, Wagner Kay-Uwe, Müller Mathias, Stoiber Dagmar, Sexl Veronika Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias. Oncotarget 2011, 2:1043-1054.
42. Klover P.J., Muller W.J., Robinson G.W., Pfeiffer R.M., Yamaji D., Hennighausen L. Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. Neoplasia 2010, 12:899-905.
43. Kim H.S., Lee M.S. STAT1 as a key modulator of cell death. Cell. Signal. 2007, 19:454-465.
44. Chan S.R., Vermi W., Luo J., Lucini L., Rickert C., Fowler A.M., Lonardi S., Arthur C., Young L.J., Levy D.E., Welch M.J., Cardiff R.D., Schreiber R.D. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res. 2012, 14:R16.
45. Okamura H., Tsutsi H., Komatsu T., Yutsudo M., Hakura A., Tanimoto T., Torigoe K., Okura T., Nukada Y., Hattori K., et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995, 378:88-91.
46. Chaudhry U.I., Kingham T.P., Plitas G., Katz S.C., Raab J.R., DeMatteo R.P. Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth. Cancer Res. 2006, 66:10497-10504.
47. Li Q., Carr A.L., Donald E.J., Skitzki J.J., Okuyama R., Stoolman L.M., Chang A.E. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern. Cancer Res. 2005, 65:1063-1070.
48. Müller J., Feige K., Wunderlin P., Hödl A., Meli M.L., Seltenhammer M., Grest P., Nicolson L., Schelling C., Heinzerling L.M. Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses. J. Immunother. 2011, 34:58-64.